Search research articles
Contact Us
Filters
Showing results (191-200 of 247) with videos related to
Page
of 25
Sort By:
Journal for Immunotherapy of Cancer
|
October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Cancer Research Communications
|
October 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Dejan Juric, Daniel Anderson, Afshin Dowlati, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Molecular Cancer Therapeutics
|
October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Med (New York, N.Y.)
|
February 8, 2021
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Edwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Cancer Cell
|
April 16, 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
BMJ Oncology
|
January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
Chad Tang, Genevieve P Hartley, Coline Couillault, et al.
JCO Precision Oncology
|
September 14, 2020
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
Rodrigo Dienstmann, Elena Garralda, Susana Aguilar, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 247) with videos related to
Sort By:
Page
of 25
Journal for Immunotherapy of Cancer
|
October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Cancer Research Communications
|
October 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Dejan Juric, Daniel Anderson, Afshin Dowlati, et al.
JCO Precision Oncology
|
February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Carmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Molecular Cancer Therapeutics
|
October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Med (New York, N.Y.)
|
February 8, 2021
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Edwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Cancer Cell
|
April 16, 2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
BMJ Oncology
|
January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
Chad Tang, Genevieve P Hartley, Coline Couillault, et al.
JCO Precision Oncology
|
September 14, 2020
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
Rodrigo Dienstmann, Elena Garralda, Susana Aguilar, et al.
Page
of 25